Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.

[1]  R. Bouabdallah,et al.  Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.

[2]  R. Storb,et al.  Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. , 2005, Blood reviews.

[3]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Radich,et al.  Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2004, Blood.

[5]  C. Flowers,et al.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.

[6]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review , 2004, Springer Seminars in Immunopathology.

[7]  R. Bouabdallah,et al.  Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level , 2004, Transfusion.

[8]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[9]  F. Baron,et al.  T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation , 2003, Transplantation.

[10]  F. Baron,et al.  Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  E. Estey,et al.  Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. , 2003, Blood.

[12]  F. Baron,et al.  Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion , 2003, British journal of haematology.

[13]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[14]  R. Brand,et al.  Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning , 2003, Leukemia.

[15]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[16]  F. Baron,et al.  Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. , 2003, Haematologica.

[17]  F. Baron,et al.  Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation , 2002, Transplantation.

[18]  R. Storb,et al.  Engraftment of early erythroid progenitors is not delayed after non‐myeloablative major ABO‐incompatible haematopoietic stem cell transplantation , 2002, British journal of haematology.

[19]  F. Baron,et al.  Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. , 2002, Experimental hematology.

[20]  F. Baron,et al.  Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells. , 2002, Journal of hematotherapy & stem cell research.

[21]  Y. Beguin,et al.  Nonmyeloablative allogeneic hematopoietic stem cell transplantation. , 2002, Journal of hematotherapy & stem cell research.

[22]  Y. Beguin.  Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. , 2002, Haematologica.

[23]  R. Storb,et al.  Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. , 2001, Blood.

[24]  S. Rowley.  Hematopoietic stem cell transplantation between red cell incompatible donor–recipient pairs , 2001, Bone Marrow Transplantation.

[25]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[26]  B. Sautois,et al.  Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation. , 2001, Haematologica.

[27]  R. Means.  The anaemia of infection. , 2000, Bailliere's best practice & research. Clinical haematology.

[28]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[29]  R. Storb,et al.  Mixed chimerism: preclinical studies and clinical applications. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[31]  G. Fillet,et al.  Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. , 1998, Haematologica.

[32]  S. Brunet,et al.  Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin , 1997, Bone Marrow Transplantation.

[33]  A. Bosi,et al.  Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. , 1996, Bone marrow transplantation.

[34]  B. Danielson.  R-HuEPO hyperesponsiveness : who and why ? , 1995 .

[35]  C. Winearls,et al.  Chairman's Workshop Report R-HuEPO hyporesponsiveness—who and why? , 1995 .

[36]  J. Szer,et al.  Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. , 1995, Bone marrow transplantation.

[37]  T. Drüeke,et al.  R-HuEPO hyporesponsiveness--who and why? , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  M. Cazzola,et al.  Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation. , 1994, Bone marrow transplantation.

[39]  F. Mandelli,et al.  A controlled trial of recombinant human erythropoietin after bone marrow transplantation. , 1994, Blood.

[40]  P. Ljungman,et al.  Treatment with erythropoietin after allogeneic bone marrow transplantation: a randomized, double-blind study. , 1994, Transplantation Proceedings.

[41]  B. W. Brown,et al.  A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. , 1994, Blood.

[42]  F. Locatelli,et al.  Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. , 1994, Bone marrow transplantation.

[43]  B. Sautois,et al.  Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen , 1993 .

[44]  G. Fillet,et al.  Dynamics of erythropoietic recovery following bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. , 1993, Bone marrow transplantation.

[45]  G. Fillet,et al.  Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. , 1993, Blood.

[46]  M. Otero,et al.  Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. , 1992, Bone marrow transplantation.

[47]  M. Cazzola,et al.  Recombinant human erythropoietin is effective in correcting erythropoietin‐deficient anaemia after allogeneic bone marrow transplantation , 1992, British journal of haematology.

[48]  A. Bosi,et al.  Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO-compatible, HLA-identical, allogeneic bone marrow transplant patients. , 1992, Leukemia.

[49]  G. Fillet,et al.  Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants. , 1991, Blood.